Me too-drugs with limited benefits — the tale of regorafenib for HCC

Me too-drugs with limited benefits — the tale of regorafenib for HCCMe too-drugs with limited benefits — the tale of regorafenib for HCC, Published online: 28 November 2017; doi:10.1038/nrclinonc.2017.190Me too-drugs with limited benefits — the tale of regorafenib for HCC

Source: Nature Clinical Practice Oncology - November 28, 2017 Category: Cancer & Oncology Authors: Bishal Gyawali Vinay Prasad Source Type: research